Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

In September 2025, AusperBio completed participant enrolment in two Phase II studies evaluating AHB-137 for the functional cure of CHB. "AusperBio concludes enrolment in Phase III AUSHINE trial" was ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART.

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient ...